MBCC 2019 Volume 1 - PERSEPHONE Trial Offers New Options for HER2+ Disease

For patients with HER2-positive disease, the results presented from the phase III PERSEPHONE trial showed patients with early-stage breast cancer could receive shorter treatment to achieve the same outcome. Researchers demonstrated a 6-month course of adjuvant trastuzumab was noninferior for disease-free survival (DFS) compared with the standard 12-month schedule. Overall, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% for patients on the 6-month arm. A full debrief on the results from this trial and how they inform your practice, will be presented at this year’s meeting.


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By